Hikma Pharmaceuticals/£HIK
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company headquartered in London, United Kingdom. It specializes in the development, manufacturing, and marketing of a broad portfolio of branded and non-branded generic and in-licensed pharmaceutical products. The company operates across three main segments: Injectables, Generics, and Branded, serving hospitals, pharmacies, and wholesalers. Hikma was founded in 1978 in Amman, Jordan, and has since expanded its operations globally, maintaining a significant presence in the Middle East and North Africa, the United States, and Europe. Its strategic positioning is supported by its extensive manufacturing capabilities and a strong commitment to quality and regulatory compliance.
Ticker
£HIK
Sector
Primary listing
LSE
Employees
9,500
Headquarters
Website
HIK Metrics
BasicAdvanced
£3.5B
12.54
£1.27
0.60
£0.63
3.94%
Price and volume
Market cap
£3.5B
Beta
0.6
52-week high
£23.60
52-week low
£15.22
Average daily volume
838K
Dividend rate
£0.63
Financial strength
Current ratio
1.244
Quick ratio
0.653
Long term debt to equity
33.007
Total debt to equity
61.074
Dividend payout ratio (TTM)
47.71%
Interest coverage (TTM)
8.17%
Profitability
EBITDA (TTM)
580.426
Gross margin (TTM)
43.03%
Net profit margin (TTM)
11.54%
Operating margin (TTM)
18.03%
Effective tax rate (TTM)
19.26%
Revenue per employee (TTM)
£258,300
Management effectiveness
Return on assets (TTM)
6.97%
Return on equity (TTM)
15.38%
Valuation
Price to earnings (TTM)
12.542
Price to revenue (TTM)
1.436
Price to book
1.38
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
20.262
Free cash flow yield (TTM)
4.94%
Free cash flow per share (TTM)
0.785
Dividend yield (TTM)
3.94%
Growth
Revenue change (TTM)
6.60%
Earnings per share change (TTM)
31.16%
3-year revenue growth (CAGR)
8.04%
10-year revenue growth (CAGR)
8.22%
3-year earnings per share growth (CAGR)
3.66%
10-year earnings per share growth (CAGR)
3.22%
3-year dividend per share growth (CAGR)
15.16%
10-year dividend per share growth (CAGR)
12.44%
What the Analysts think about HIK
Analyst ratings (Buy, Hold, Sell) for Hikma Pharmaceuticals stock.
Bulls say / Bears say
Group revenues rose 6% year-over-year to $1.658 billion in H1 2025, driven by robust demand across MENA and North America, and Hikma reaffirmed its full-year guidance for 4–6% revenue growth and $730 million–$770 million in core operating profit (Reuters)
On 17 July 2025, Hikma secured a $250 million six-year financing agreement with the International Finance Corporation to expand its local manufacturing capacity in MENA, strengthening its balance sheet and supporting regional growth initiatives (Reuters)
During H1 2025, Hikma launched 33 new products and submitted 21 regulatory filings, underpinning its guidance for 7–9% Injectables revenue growth as it builds pipeline momentum (Reuters)
Hikma agreed to pay $50 million to settle a U.S. antitrust class-action lawsuit over delaying its generic sodium oxybate launch, exposing the company to legal risk and potential reputational damage (Reuters)
The group cut its full-year core operating margin outlook for its Injectables unit to 32–33% from its prior mid-30s forecast, citing a strong euro and higher costs, highlighting margin pressure from FX headwinds and product mix shifts (Reuters)
The UK’s Voluntary Scheme for Branded Medicines Pricing, Access and Growth increased required rebates to nearly 23%, intensifying pricing pressure on branded medicines and potentially squeezing Hikma’s UK margin profile (FT)
Data summarised monthly by Lightyear AI. Last updated on 1 Nov 2025.
HIK Financial Performance
Revenues and expenses
HIK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hikma Pharmaceuticals stock?
Hikma Pharmaceuticals (HIK) has a market cap of £3.5B as of November 08, 2025.
What is the P/E ratio for Hikma Pharmaceuticals stock?
The price to earnings (P/E) ratio for Hikma Pharmaceuticals (HIK) stock is 12.54 as of November 08, 2025.
Does Hikma Pharmaceuticals stock pay dividends?
Yes, the Hikma Pharmaceuticals (HIK) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is £0.62718 and the yield is 3.94%. Hikma Pharmaceuticals has a payout ratio of 47.71% on a trailing twelve-month basis.
When is the next Hikma Pharmaceuticals dividend payment date?
The next Hikma Pharmaceuticals (HIK) dividend payment date is unconfirmed.
What is the beta indicator for Hikma Pharmaceuticals?
Hikma Pharmaceuticals (HIK) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.